Short- and long-term safety of glaucoma drugs

Joel S. Schuman

Research output: Contribution to journalReview articlepeer-review


Glaucoma, a leading cause of blindness worldwide, is a chronic neurodegenerative disorder. Patients with glaucoma may require long-term administration of intraocular pressure (IOP)-lowering medications. These medications belong to several classes of molecules including β-adrenergic blockers, cholinergic agents, α -adrenergic agonists, carbonic anhydrase inhibitors and ocular hypotensive lipids. Most adverse effects associated with IOP-lowering medications are mild and ocular in nature; however, several of them are associated with systemic risks as well as serious ocular effects, especially following chronic use. The following review discusses the acute and long-term effects of commonly used IOP-lowering medications.

Original languageEnglish (US)
Pages (from-to)181-194
Number of pages14
JournalExpert Opinion on Drug Safety
Issue number2
StatePublished - Jul 1 2002


  • carbonic anhydrase inhibitors
  • cholinergic agents
  • glaucoma
  • long-term safety
  • ocular hypotensive lipids
  • α-adrenergic agonists
  • β-adrenergic blockers

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Short- and long-term safety of glaucoma drugs'. Together they form a unique fingerprint.

Cite this